Liraglutide alleviates myocardial ischemia‒reperfusion injury in diabetic mice-Reference-Cited by-同舟云学术

Liraglutide alleviates myocardial ischemia‒reperfusion injury in diabetic mice

Published:2023-07 Issue: Volume:572 Page:111954
ISSN:0303-7207
Container-title:Molecular and Cellular Endocrinology
language:en
Short-container-title:Molecular and Cellular Endocrinology

Author:

Fang Binbin^ORCID,Liu Fen,Yu Xiaolin,Luo Junyi,Zhang Xuehe,Zhang Tong^ORCID,Zhang Jixin,Yang Yining,Li Xiaomei

Publisher

Elsevier BV

Subject

Endocrinology,Molecular Biology,Biochemistry

Reference32 articles.

1. Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: analyses from the LYDIA trial;Ahmad;Diabetes Obes. Metabol.,2021

2. Effect of ischemic postconditioning on myocardial function and infarct size following reperfusion injury in diabetic rats pretreated with vildagliptin;Bayrami;Naunyn-Schmiedeberg’s Arch. Pharmacol.,2018

3. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats;Cai;Biochem. Biophys. Res. Commun.,2022

4. GAS5 regulates diabetic cardiomyopathy via miR2213p/p27 axisassociated autophagy;Chen;Mol. Med. Rep.,2021

5. Dapagliflozin and ticagrelor have additive effects on the attenuation of the activation of the NLRP3 inflammasome and the progression of diabetic cardiomyopathy: an AMPK-mTOR interplay;Chen;Cardiovasc. Drugs Ther.,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The benefits of oral glucose-lowering agents: GLP-1 receptor agonists, DPP-4 and SGLT-2 inhibitors on myocardial ischaemia/reperfusion injury;European Journal of Pharmacology;2024-08

2. Unlocking the miRNA-34a-5p/TGF-β and HMGB1/PI3K/Akt/mTOR crosstalk participate in the enhanced cardiac protection of liraglutide against isoproterenol-induced acute myocardial injury rat model;International Immunopharmacology;2024-01

3. GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway;Frontiers in Immunology;2023-11-20